Inactive Instrument

Press Releases Theravance Inc Nasdaq

Equities

US88338T1043

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 24	Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	CI
Mar. 04	Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	Apr. 25	AQ
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	Apr. 24	BU
Innoviva: Q4 Earnings Snapshot	Feb. 29	AQ
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress	Feb. 29	BU
Innoviva Specialty Therapeutics Appoints David Altarac, MD, as Chief Medical Officer	Feb. 06	AQ
Innoviva Specialty Therapeutics - Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea	Nov. 02	AQ
Innoviva: Q3 Earnings Snapshot	Nov. 01	AQ
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress	Nov. 01	BU
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea	Nov. 01	BU
Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week 2023	23-10-12	AQ
Innoviva to Participate in the Cantor Global Healthcare Conference	23-09-19	BU
Innoviva - XACDURO, the First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia in Adults	23-09-19	AQ
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults	23-09-18	BU
Innoviva Appoints Stephen Basso as Chief Financial Officer	23-08-28	AQ
Innoviva Appoints Stephen Basso as Chief Financial Officer	23-08-25	BU
Innoviva: Q2 Earnings Snapshot	23-08-02	AQ
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress	23-08-02	BU
Purcell & Lefkowitz LLP Is Investigating Innoviva, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors	23-07-13	PR
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics	23-07-12	AQ
Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference	23-06-06	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Theravance Inc Nasdaq

Equities

US88338T1043

Press Releases

Filters